Senseonics Holdings Director Douglas A. Roeder Buys $176K of Stock
Douglas A. Roeder, Director, bought 17,041 shares of Senseonics Holdings, Inc. at $10.32 a share, worth $176K in total on Nov 13, 2026. Shares held after the trade: 189,712 (+9.9%).
Senseonics reported total revenue of $19.6 million for the third quarter of 2026, a significant increase from $8.1 million in the prior year period. However, the company experienced a widening net loss of $101.7 million for the first nine months of 2026, driven by a substantial increase in selling, general, and administrative expenses.
Senseonics reported Q3 2026 revenue of $19.6 million, a 140% increase year-over-year, driven by strong U.S. commercial execution of the Eversense 365 CGM system. The company raised its full-year 2026 revenue guidance to $68-$70 million and improved its gross margin to 62%. Management highlighted the expansion of the EON Care network and a new strategic partnership with Beta Bionics for insulin pump integration.
Term
Q3 2026
“Our approximately 140% year-over-year revenue growth in Q3 reflects the progress we are making in executing our commercial strategy and driving increased awareness and demand for Eversense 365. Recent investments in commercial infrastructure are expanding patient access, supporting our growth and improving gross margins.”
Tim Goodnow, PhD, President and Chief Executive Officer
“Multiple initiatives to expand awareness and access create opportunities to bring Eversense to patients and prescribers we had not previously reached. As EON Care grows, we can extend our direct-to-consumer and health care provider outreach into additional markets with an insertion option already in place.”